Clinical presentation and neurovascular manifestations of cardiac myxomas and papillary fibroelastomas: a retrospective single-institution cohort study.
benign cardiac neoplasms
cardiac myxomas
cardiac papillary fibroelastoma
cerebrovascular events
neutrophil–lymphocyte (N/L ratio)
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
05
2023
accepted:
11
08
2023
medline:
18
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
Primary cardiac tumors are often benign and commonly present as cardiac myxomas (CMs) or papillary fibroelastomas (CPFEs). There is a paucity of prognostic indicators for tumor burden or potential for embolic cerebrovascular events (CVEs). This study was performed to address these gaps. Medical records at the University of Florida Health Shands Hospital between 1996 and 2021 were screened to identify patients with CMs or CPFEs. Clinical features, echocardiographic reports, and CVE outcomes were quantitatively assessed. A total of 55 patients were included in the study: 28 CM (50.9%) and 27 CPFE (49.1%) patients. Baseline patient characteristics were similar among patients. The neutrophil-lymphocyte ratio was correlated ( The neutrophil-lymphocyte ratio may prognosticate tumor size and recurrence of neurologic events. An increased risk of CVE within 5 years of mass resection is almost exclusive to patients initially presenting with CVEs.
Sections du résumé
Background
UNASSIGNED
Primary cardiac tumors are often benign and commonly present as cardiac myxomas (CMs) or papillary fibroelastomas (CPFEs). There is a paucity of prognostic indicators for tumor burden or potential for embolic cerebrovascular events (CVEs). This study was performed to address these gaps.
Methods
UNASSIGNED
Medical records at the University of Florida Health Shands Hospital between 1996 and 2021 were screened to identify patients with CMs or CPFEs. Clinical features, echocardiographic reports, and CVE outcomes were quantitatively assessed.
Results
UNASSIGNED
A total of 55 patients were included in the study: 28 CM (50.9%) and 27 CPFE (49.1%) patients. Baseline patient characteristics were similar among patients. The neutrophil-lymphocyte ratio was correlated (
Conclusion
UNASSIGNED
The neutrophil-lymphocyte ratio may prognosticate tumor size and recurrence of neurologic events. An increased risk of CVE within 5 years of mass resection is almost exclusive to patients initially presenting with CVEs.
Identifiants
pubmed: 37719971
doi: 10.3389/fcvm.2023.1222179
pmc: PMC10503431
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1222179Informations de copyright
© 2023 Mathavan, Mathavan, Krekora, Mathavan, Rodriguez, Altshuler, Nguyen and Ruzieh.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Pathol Clin Res. 2017 Mar 07;3(2):100-104
pubmed: 28451458
BMJ Case Rep. 2016 Nov 22;2016:
pubmed: 27879304
Medicine (Baltimore). 2018 Jun;97(26):e11138
pubmed: 29952958
Medicine (Baltimore). 2001 May;80(3):159-72
pubmed: 11388092
Folia Histochem Cytobiol. 2021;59(4):212-225
pubmed: 34878643
Front Neurol. 2021 Sep 24;12:686983
pubmed: 34630275
ISRN Cardiol. 2012;2012:906109
pubmed: 22792486
Case Rep Cardiol. 2017;2017:8185601
pubmed: 28458927
J Med Ultrason (2001). 2012 Jul;39(3):173-5
pubmed: 27278978
Medicine (Baltimore). 2018 Sep;97(37):e12397
pubmed: 30213011
J Cardiothorac Surg. 2016 Feb 02;11:22
pubmed: 26832806
Ann Transl Med. 2021 Jul;9(13):1047
pubmed: 34422959
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
J Thorac Cardiovasc Surg. 2022 Jul 16;:
pubmed: 35989118
Front Neurol. 2018 Oct 03;9:823
pubmed: 30337904
J Am Coll Cardiol. 2021 Apr 27;77(16):2154-2155
pubmed: 33888255
Int Heart J. 2015;56(1):18-21
pubmed: 25742940
Am J Cardiol. 2008 Sep 15;102(6):653-7
pubmed: 18773982
J Cardiovasc Surg (Torino). 1996 Dec;37(6 Suppl 1):113-7
pubmed: 10064362
Arch Med Res. 2015 Apr;46(3):199-206
pubmed: 25980945
Biomark Med. 2020 Feb;14(3):169-172
pubmed: 32053007
Curr Cardiol Rep. 2020 Oct 10;22(12):169
pubmed: 33040219
Circulation. 2021 Feb 2;143(5):e72-e227
pubmed: 33332150
Hellenic J Cardiol. 2016 Nov - Dec;57(6):441-444
pubmed: 27915010
Cardiovasc Pathol. 1992 Apr-Jun;1(2):161-6
pubmed: 25990128
World J Cardiol. 2022 Apr 26;14(4):206-219
pubmed: 35582466
Struct Heart. 2023 Feb 10;7(4):100154
pubmed: 37520139
Pathol Res Pract. 2013 Apr;209(4):208-14
pubmed: 23455367
Am Heart J. 2003 Sep;146(3):404-10
pubmed: 12947356
Eur Heart J Case Rep. 2022 Jul 29;6(8):ytac315
pubmed: 35935401
Sci Rep. 2019 Dec 23;9(1):19673
pubmed: 31873162
Circulation. 2001 Jun 5;103(22):2687-93
pubmed: 11390338
Heliyon. 2020 Jul 23;6(7):e04535
pubmed: 32743107
Int J Mol Sci. 2022 Mar 26;23(7):
pubmed: 35408994
Expert Rev Cardiovasc Ther. 2016;14(5):573-7
pubmed: 26878164
Thromb Haemost. 2011 Oct;106(4):591-9
pubmed: 21866299
Oncol Lett. 2018 Oct;16(4):4635-4639
pubmed: 30214598
Expert Rev Cardiovasc Ther. 2015 Apr;13(4):369-75
pubmed: 25797902
Braz J Cardiovasc Surg. 2018 Mar-Apr;33(2):162-168
pubmed: 29898146
World J Clin Cases. 2017 Jan 16;5(1):9-13
pubmed: 28138441
J Am Coll Cardiol. 2015 Jun 9;65(22):2420-9
pubmed: 26046736
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371
pubmed: 28314623
Gen Thorac Cardiovasc Surg. 2011 Oct;59(10):712-4
pubmed: 21984141
Tex Heart Inst J. 2001;28(1):3-7
pubmed: 11330738